Fig. 7
From: Vesicular glutamate release from central axons contributes to myelin damage
A single QNZ-46 pre-treatment produces high levels of white matter and gray matter neuro-protection. a–c Brain lesion volume 24 h post-tMCAO. d–f Functional recovery prior to the killing. Drug treatment significantly improved the outcome in all measures. ANOVA with Holm−ŠÃdák post test. P values: b ***0.0000; c **0.000; e **0.004; f *0.011. Mann−Whitney test; d *<0.05. g–j YFP expression (green) and luxol fast-blue/cresyl violet (blue/purple: myelin) in Thy-1-YFP mice. g YFP(+) axons project within the external capsule which is extensively myelinated in contralateral (Contra) and ipsilateral (Ipsi) hemispheres in sham-operated mice. Higher power micrographs are shown at the bottom. h Mice treated with vehicle show disruption and loss of axonal YFP that extends to both hemispheres and loss of myelin within the ipsilateral white matter. i Drug-treated mice retain YFP(+) axons and myelin staining in both hemispheres. j Myelin stain density is significantly reduced in the vehicle-treated group (***0.0002), and preserved by QNZ-46 pre-treatment (**0.005). Scale bars = 100 μm
